Find Abrocitinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Abrocitinib, 1622902-68-4, Pf-04965842, Cibinqo, Abrocitinib [usan], 73sm5sf3or
Molecular Formula
C14H21N5O2S
Molecular Weight
323.42  g/mol
InChI Key
IUEWXNHSKRWHDY-UHFFFAOYSA-N
FDA UNII
73SM5SF3OR

Abrocitinib
Abrocitinib is under investigation in clinical trial NCT03796676 (JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis).
Abrocitinib is a Janus Kinase Inhibitor. The mechanism of action of abrocitinib is as a Janus Kinase Inhibitor, and P-Glycoprotein Inhibitor.
1 2D Structure

Abrocitinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
2.1.2 InChI
InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)
2.1.3 InChI Key
IUEWXNHSKRWHDY-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3
2.2 Other Identifiers
2.2.1 UNII
73SM5SF3OR
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-propanesulfonamide, N-(cis-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)-

2. Abrocitinib

3. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide

4. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide

5. Pf-04965842

2.3.2 Depositor-Supplied Synonyms

1. Abrocitinib

2. 1622902-68-4

3. Pf-04965842

4. Cibinqo

5. Abrocitinib [usan]

6. 73sm5sf3or

7. Chembl4101725

8. N-[3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide

9. N-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide

10. 1-propanesulfonamide, N-(cis-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)-

11. N-(3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, Cis-

12. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide

13. N-[cis-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide

14. Unii-73sm5sf3or

15. D7d

16. N-((1s,3s)-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide

17. N-((1s,3s)-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide

18. Abrocitinib [inn]

19. Abrocitinib [jan]

20. Abrocitinib (jan/usan)

21. Abrocitinib [who-dd]

22. Gtpl9991

23. Chembl3655081

24. Schembl15970412

25. Schembl15970413

26. Pf-04965842(abrocitinib)

27. Bdbm159748

28. Dtxsid301126581

29. Pf-04965842 (abrocitinib)

30. Bcp30441

31. Ex-a3037

32. Xpc90268

33. Ac8575

34. Bdbm50243847

35. Mfcd30187577

36. S8765

37. Zb1566

38. Zinc261115849

39. Db14973

40. Sb18849

41. Compound 25 [pmid: 29298069]

42. Ncgc00601823-02

43. Ac-36318

44. As-84437

45. Sy248874

46. Hy-107429

47. Cs-0028460

48. Pf04965842

49. D11400

50. Us9035074, 2

51. A936574

52. Pf-04965842, >=98% (hplc)

53. Pf-04965842pf-04965842

54. Pf-04965842; Pf 04965842; Pf04965842

55. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide

56. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide

57. Abrocitinib;n-[cis-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide

2.4 Create Date
2014-10-06
3 Chemical and Physical Properties
Molecular Weight 323.42 g/mol
Molecular Formula C14H21N5O2S
XLogP31.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count6
Exact Mass323.14159610 g/mol
Monoisotopic Mass323.14159610 g/mol
Topological Polar Surface Area99.4 Ų
Heavy Atom Count22
Formal Charge0
Complexity474
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
ABROCITINIB
5.2.2 FDA UNII
73SM5SF3OR
5.2.3 Pharmacological Classes
Mechanisms of Action [MoA] - P-Glycoprotein Inhibitors
5.3 ATC Code

D11AH


D - Dermatologicals

D11 - Other dermatological preparations

D11A - Other dermatological preparations

D11AH - Agents for dermatitis, excluding corticosteroids

D11AH08 - Abrocitinib


Drugs in Development

read-more
read-more

Details:

Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Eczema.


Lead Product(s): Abrocitinib,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 04, 2025

blank

01

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Eczema.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 04, 2025

blank

Details:

Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Abrocitinib,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 04, 2025

blank

02

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 04, 2025

blank

Details:

Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Post-Acute COVID-19 Syndrome.


Lead Product(s): Abrocitinib,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 19, 2024

blank

03

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Post-Acute COVID-19 Syndrome.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 19, 2024

blank

Details:

Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hand Dermatoses.


Lead Product(s): Abrocitinib,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 28, 2024

blank

04

Innovaderm

Canada
arrow
PEGS Boston Summit
Not Confirmed

Innovaderm

Canada
arrow
PEGS Boston Summit
Not Confirmed

Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hand Dermatoses.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 28, 2024

blank

Details:

Glenmark and Pfizer will co-market abrocitinib, a JAK1 inhibitor providing rapid itch relief and sustained control in India as Jabryus and Cibinqo.


Lead Product(s): Abrocitinib,Inapplicable

Therapeutic Area: Dermatology Brand Name: Cibinqo

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Pfizer Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 31, 2024

blank

05

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Glenmark and Pfizer will co-market abrocitinib, a JAK1 inhibitor providing rapid itch relief and sustained control in India as Jabryus and Cibinqo.

Product Name : Cibinqo

Product Type : Miscellaneous

Upfront Cash : Undisclosed

January 31, 2024

blank
  • Development Update

Details:

Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.


Lead Product(s): Abrocitinib,Inapplicable

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 24, 2023

blank

06

National Institute of Diabetes and Digestive and Kidney Diseases

Country
arrow
PEGS Boston Summit
Not Confirmed

National Institute of Diabetes and Digestive and Kidney Diseases

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 24, 2023

blank

Details:

CIBINQO (abrocitinib) is an oral inhibitor of Janus kinase 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP).


Lead Product(s): Abrocitinib,Inapplicable

Therapeutic Area: Dermatology Brand Name: Cibinqo

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 10, 2023

blank

07

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : CIBINQO (abrocitinib) is an oral inhibitor of Janus kinase 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP).

Product Name : Cibinqo

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 10, 2023

blank
  • Development Update

Details:

Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoidosis.


Lead Product(s): Abrocitinib,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 25, 2023

blank

08

Yale University

Country
arrow
PEGS Boston Summit
Not Confirmed

Yale University

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoidosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 25, 2023

blank

Details:

Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Granuloma Annulare.


Lead Product(s): Abrocitinib,Inapplicable

Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: William Damsky

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 14, 2022

blank

09

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Granuloma Annulare.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 14, 2022

blank

Details:

Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Abrocitinib,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 02, 2022

blank

10

Innovaderm

Canada
arrow
PEGS Boston Summit
Not Confirmed

Innovaderm

Canada
arrow
PEGS Boston Summit
Not Confirmed

Details : Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 02, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1622902-68-4 / Abrocitinib API manufacturers, exporters & distributors?

Abrocitinib manufacturers, exporters & distributors 1

59

PharmaCompass offers a list of Abrocitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Abrocitinib manufacturer or Abrocitinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Abrocitinib manufacturer or Abrocitinib supplier.

API | Excipient name

Abrocitinib

Synonyms

1622902-68-4, Pf-04965842, Cibinqo, Abrocitinib [usan], 73sm5sf3or, Chembl4101725

Cas Number

1622902-68-4

Unique Ingredient Identifier (UNII)

73SM5SF3OR

About Abrocitinib

Abrocitinib is under investigation in clinical trial NCT03796676 (JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis).

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide Manufacturers

A N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide, including repackagers and relabelers. The FDA regulates N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide Suppliers

A N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide supplier is an individual or a company that provides N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide active pharmaceutical ingredient (API) or N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide finished formulations upon request. The N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide suppliers may include N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide API manufacturers, exporters, distributors and traders.

click here to find a list of N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide USDMF

A N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide DMF (Drug Master File) is a document detailing the whole manufacturing process of N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide active pharmaceutical ingredient (API) in detail. Different forms of N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide DMFs exist exist since differing nations have different regulations, such as N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide DMF submitted to regulatory agencies in the US is known as a USDMF. N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide USDMF includes data on N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide suppliers with USDMF on PharmaCompass.

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide Drug Master File in Korea (N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide. The MFDS reviews the N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide KDMF as part of the drug registration process and uses the information provided in the N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide KDMF to evaluate the safety and efficacy of the drug.

After submitting a N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide API can apply through the Korea Drug Master File (KDMF).

click here to find a list of N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide suppliers with KDMF on PharmaCompass.

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide suppliers with NDC on PharmaCompass.

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide GMP

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide GMP manufacturer or N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide GMP API supplier for your needs.

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide CoA

A N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide CoA (Certificate of Analysis) is a formal document that attests to N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide's compliance with N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide specifications and serves as a tool for batch-level quality control.

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide CoA mostly includes findings from lab analyses of a specific batch. For each N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide may be tested according to a variety of international standards, such as European Pharmacopoeia (N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide EP), N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty